RCS - Ondine Biomedical - Steriwave study shows 77% drop in antibiotic use

Ondine BiomedicalAnnouncement

21/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU7113Ha&default-theme=true

RNS Number : 7113H  Ondine Biomedical Inc.  21 March 2024

Non-regulatory announcement

21 March 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave study shows 77% drop in antibiotic use

Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company
pioneering light-activated antimicrobial treatments to prevent and treat
healthcare-associated infections (HAIs), announces that a UK-based study
demonstrated a significant reduction in antibiotic use following sinus
surgeries where Steriwave® was used for pre-surgical nasal decolonization.

Professor Claire Hopkins, Professor of Rhinology at King's College London and
Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust, has
reported a retrospective study showing that using Steriwave in her endoscopic
sinus surgery patients led to antibiotic use across all her patients dropping
from 22% to less than 5% - a 77% reduction. Professor Hopkins has been using
Steriwave routinely to nasally decolonise her endoscopic sinus surgery
patients at London Bridge Hospital since 2021.

Professor Hopkins commented, "I was amazed that studies show that by treating
the nose you can reduce spinal surgical site infections - so it seemed an
ideal way to reduce the risk of post-operative infection after nasal surgery.
I have seen a significant reduction in post-operative infections requiring
antibiotics, which is good for the patients, reducing the risk of
antibiotic-related side effects, and important to help prevent ever-increasing
antibiotic resistance. It needs formal controlled studies to further evaluate
the effectiveness but I am impressed with the difference that I have seen in
my practice."

Interview with Professor Hopkins: Steriwave prevents sinonasal SSIs
(https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68)

Carolyn Cross CEO of Ondine commented, "In an era of rising drug resistance,
antibiotic stewardship is of great importance.  Sinus surgery is typically
associated with high rates of routine post-operative antibiotic prescribing in
order to reduce the risk of post-operative infection. Reducing antibiotic
usage is important to curb rising antimicrobial resistance and preserve
antibiotics' effectiveness when there is no other solution. We are pleased to
be supporting Professor Hopkins' development and adoption of important new
infection control procedures that enable a marked reduction in antibiotic use
in sinus surgery patients."

Canadian hospitals have been using Ondine's light-activated antimicrobial to
reduce post-surgical infections for over 10 years without evidence of
resistance generation or patient safety issues.  Results presented at the
(https://www.londonstockexchange.com/news-article/OBI/microbiome-research-supports-use-of-steriwave/16310998)
the prestigious SPIE Photonics West
(https://www.londonstockexchange.com/news-article/OBI/microbiome-research-supports-use-of-steriwave/16310998)
conference in San Francisco, California showed that treatment with Ondine's
Steriwave® Nasal Photodisinfection System significantly reduces pathogens -
viruses, bacteria and fungi - in the nose without producing long-term adverse
effects on the nasal microbiome. This is an important finding to allay
potential concerns as to a possible side-effect of Steriwave treatment, which
has been used in over 150,000 patients with no serious adverse events
reported. Steriwave was selected as a 2024 SPIE Prism Awards finalist in the
'Biomedical' category.

 
" END"

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader
innovating light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary light activated technology, in various stages of
development.

 Ondine's light activated technology for nasal decolonisation has a CE mark
in Europe and the UK and is approved in Canada and several other countries
under the name Steriwave®. In the US, it has been granted Qualified
Infectious Disease Product designation and Fast Track status by the FDA and is
currently undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns, and many
other indications.

About Steriwave®

Ondine's Steriwave® nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an easy
to use, painless, two-step process. The photosensitizer is applied to each
nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81% i -is that pathogens do not develop
resistance to the therapy.

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections, ii  and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023, recommend
nasal decolonization for major surgical procedures. iii 

 

 

 i  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

 ii 
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

 iii  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAXBLLLZXLXBBL